Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.
BACKGROUND
Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help inform treatment decisions to enhance care of cancer patients.


OBJECTIVE
The objective was to qualitatively assess HRQoL in long-term survivors treated with BV.


METHODS
An eight-question survey assessing PRO-related aspects was developed and fielded to a subset of patients with HL or sALCL who remained in long-term follow-up after completing BV treatment in the two pivotal studies.


RESULTS
The survey was completed by 25 of 38 patients (12 with HL, 13 with sALCL). The majority of patients reported that their energy level, outlook on life, difficulties with daily activities, ability to participate in physical activities, and overall HRQoL improved compared to those before BV treatment.


CONCLUSIONS
Small sample size and lack of a baseline questionnaire or validated assessment instrument limit broad applicability of these findings to large populations of patients with HL or sALCL.


CONCLUSIONS
This is the first report of BV PRO data in R/R HL and sALCL. Given the patients' poor prognostic outcomes before stem cell transplant, these encouraging results warrant formal evaluation of PRO end points in BV trials.
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Robert
R
Chen
The Lymphoma Service of the Christie NHS Foundation Trust, Manchester, UK.
Suzanne
S
Allibone
Department of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA.
Nancy L
NL
Bartlett
Department of Hemato-Oncology, Hôpital Saint-Louis, Paris, France.
Pauline
P
Brice
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Andy
A
Chen
Lymphoma and Cancer Survivorship Stanford Comprehensive Cancer Center, Stanford, CA, USA.
Katrina
K
Pose
Lymphoma Program, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Lynn
L
Rich
Millennium Pharmaceuticals Inc., Cambridge, MA, USA.
Vijay
V
Bonthapally
Seattle Genetics, Inc., Bothell, WA, USA.
Phillip M
PM
Garfin
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle
M
Fanale
activities of daily living; brentuximab vedotin; health-related quality of life; patient well-being; pilot study